INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.
Rhea-AI Summary
INmune Bio (NASDAQ: INMB) will report year-ended December 31, 2025 financial results and provide a corporate update on Monday, March 30, 2026 at 4:30 PM Eastern Time. Management will host a conference call and live audio webcast; replay available through April 13, 2026.
Dial-in numbers, conference ID, webcast link, and replay details were provided for investor access.
Positive
- None.
Negative
- None.
News Market Reaction – INMB
In the Mar 24 session, INMB declined 4.84%, reflecting a moderate negative market reaction. Argus tracked a peak move of +3.4% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 19 | Clinical trial spotlight | Positive | -1.6% | Phase 2 MINDFuL Alzheimer’s trial highlighted as successful inflammation-targeted design. |
| Feb 23 | Webinar announcement | Positive | -3.8% | Upcoming webinar outlining XPro1595 registrational pathway and Phase 3 roadmap. |
| Feb 19 | Clinical data webinar | Positive | -2.2% | Planned webinar to present new CORDStrom Phase III data in RDEB. |
| Feb 12 | FDA alignment | Positive | -6.4% | FDA alignment on integrated Phase 2b/3 registration pathway for XPro1595. |
| Feb 10 | Regulatory progress | Positive | +3.9% | CORDStrom pre-submission to UK MHRA and plans for global MAA filings. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive clinical and regulatory updates often saw negative price reactions, with only one of the last five events showing an aligned move.
Over the last few months, INMB issued multiple pipeline and regulatory updates. These included progress on CORDStrom™ toward UK marketing authorization and MissionEB Phase III data, plus FDA-aligned plans for an integrated Phase 2b/3 program of XPro1595 in early Alzheimer’s. Despite these seemingly constructive milestones, shares frequently traded down in the 24 hours after such news, making today’s pre-announced year-end 2025 results date a contrast to the more clinically focused prior catalysts.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Management to host conference call and webcast at 4:30 pm ET on that day
Boca Raton, Florida, March 24, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it will host a conference call on Monday, March 30th, 2026 at 4:30pm EDT to discuss results for its year ended December 31, 2025, and to provide a corporate update.
Conference Call Information
To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio First Quarter Conference Call when reaching the operator.
Date: March 30th, 2026
Time: 4:30 PM Eastern Time
Participant Dial-in: 1-800-343-4136 Participant Dial-in (international): +1-203-518-9843
Conference ID: INMUNE
A live audio webcast of the call can be accessed using this link or clicking here:
https://viavid.webcasts.com/starthere.jsp?ei=1748958&tp_key=96ca7c85d7
A replay will be available approximately 3 hours after the call through April 13, 2026 by dialing 1-844-512-2921 or 1-412-317-6671 (international) and entering PIN no. 11160807.
About INmune Bio Inc.
INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has three product platforms: (1) CORDStrom™, a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that recently completed a blinded randomized trial in recessive dystrophic epidermolysis bullosa; (2) XPro™, a Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform designed to selectively neutralize soluble TNF, a key driver of inflammation and innate immune dysfunction; and (3) INKmune®, a cell-based medicine designed to prime a patient’s natural killer cells to eliminate minimal residual disease in patients with cancer. To learn more, please visit www.inmunebio.com.
Forward Looking Statements
Clinical trials are in early stages, and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, including trial results, timing of key milestones, future plans or expectations, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates, may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDstrom™, XPro1595™ (XPro™, pegipanermin), and INKmune®™ have either finished clinical trials, are still in clinical trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA), the UK MHRA or any regulatory body and there cannot be any assurance that they will be approved by the FDA, the UK MHRA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.
Company Contact:
David Moss
Chief Executive Officer
(561) 710-0512
info@inmunebio.com
Daniel Carlson
Head of Investor Relations
(415) 509-4590
dcarlson@inmunebio.com
